28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
An ERICA score of 2 or greater indicates probable AD with high diagnostic accuracy. © RSNA, 2018 Online supplemental material is available for this article. 3 key findings →
Participants: 20 Evidence: moderate
Full summary, score breakdown and related studies → Original source
It is possible to create a blood-based screening algorithm that works across both serum and plasma that provides a comparable screening accuracy to that obtained from CSF analyses. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
There is an urgent need for biomarkers in plasma to identify Alzheimer's disease (AD). 3 key findings →
Participants: 142 Evidence: low
Full summary, score breakdown and related studies → Original source
These findings indicate that although plasma and CSF neurogranin may reflect the volume of acute cerebral ischemia, this synaptic protein is less likely to be a potential AIS biomarker. 4 key findings →
Participants: 50 Evidence: low
Full summary, score breakdown and related studies → Original source
Diagnosis of the progressive neurodegenerative disorder Alzheimer's disease (AD) can only definitively be made postmortem. 4 key findings →
Participants: 270 Evidence: moderate
Full summary, score breakdown and related studies → Original source
High plasma HDL cholesterol was observationally associated with increased risk of any dementia and Alzheimer's disease, suggesting that HDL cholesterol can be used as an easily accessible plasma biomarker for individual risk assessment. 5 key findings →
Participants: 111 Evidence: low
Full summary, score breakdown and related studies → Original source
An ideal diagnostic test for Alzheimer's disease (AD) should be non-invasive and easily applicable. 1 key finding →
Participants: 155 Evidence: low
Full summary, score breakdown and related studies → Original source
We conducted virus-isolation studies on 56 specimens from the nervous system of 45 patients in order to determine whether human T-cell lymphotropic virus Type III (HTLV-III) is directly involved in the pathogenesis of the neurologic disorders frequently encountered in the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. 2 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source
Biomarkers are urgently needed for the diagnosis and monitoring of disease progression in Parkinson's disease. 5 key findings →
Participants: 117 Evidence: low
Full summary, score breakdown and related studies → Original source
The OCS-Plus represents a major methodological advance in dementia studies in LMICs, and enhances understanding of cognitive aging. 1 key finding →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Decades of research has established a shift from an "eveningness" preference to a "morningness" preference with increasing age. 4 key findings →
Participants: 169 Evidence: low
Full summary, score breakdown and related studies → Original source
Digital assessments are effective at identifying at-risk individuals, supporting their utility as low-burden tools for early AD detection and monitoring. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This work demonstrates a mobile version of VisMET capable of estimating the presence of cognitive impairment. 1 key finding →
Participants: 250 Evidence: low
Full summary, score breakdown and related studies → Original source
We investigated whether a validated computerized cognitive test, the Computerized Assessment of Mild Cognitive Impairment (CAMCI), could be independently completed by older primary care patients. 1 key finding →
Participants: 130 Evidence: low
Full summary, score breakdown and related studies → Original source
Apolipoprotein E (apoE) is associated with Alzheimer's neurofibrillary tangles and beta-amyloid protein in senile plaques. 3 key findings →
Participants: 91 Evidence: low
Full summary, score breakdown and related studies → Original source
Genome-wide association studies of neurological diseases have identified thousands of variants associated with disease phenotypes. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Age-related cognitive decline is likely promoted by accumulated brain injury due to chronic conditions of aging, including neurodegenerative and vascular disease. 4 key findings →
Participants: 749 Evidence: moderate
Full summary, score breakdown and related studies → Original source
There is an urgent need to develop molecular biomarkers of brain age in order to advance our understanding of age related neurodegeneration. 3 key findings →
Participants: 700 Evidence: low
Full summary, score breakdown and related studies → Original source
The neocortex is disproportionately expanded in human compared with mouse 1,2 , both in its total volume relative to subcortical structures and in the proportion occupied by supragranular layers composed of neurons that selectively make connections within the neocortex and with other telencephalic structures. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This transcriptomic network analysis of 19 brain regions provides a comprehensive assessment of the critical molecular pathways associated with AD pathology and offers new insights into molecular mechanisms underlying selective regional vulnerability to AD at different stages of the progression of cognitive compromise and development of the canonical neuropathological lesions of AD. 5 key findings →
Participants: 125 Evidence: low
Full summary, score breakdown and related studies → Original source
Patients with Alzheimer's disease (AD) and Parkinson's disease (PD) often have overlap in clinical presentation and brain neuropathology suggesting that these two diseases share common underlying mechanisms. 1 key finding →
Participants: 80 Evidence: low
Full summary, score breakdown and related studies → Original source
Recent studies indicate that the adaptive immune system plays a role in Lewy body dementia (LBD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In Alzheimer's disease, tau pathology spreads hierarchically from the inferior temporal lobe throughout the cortex, ensuing cognitive decline and dementia. 4 key findings →
Participants: 55 Evidence: low
Full summary, score breakdown and related studies → Original source
Elevated FTP-PET reflects Braak IV or greater neuropathology. 3 key findings →
Participants: 26 Evidence: low
Full summary, score breakdown and related studies → Original source
This evaluation shows an [ 18 F]MK-6240 distribution in concordance with postmortem studies and that simplified quantitative approaches such as the SUVR offer valid estimates of neurofibrillary tangle load 90 min post injection. [ 18 F]MK-6240 is a promising tau tracer with the potential to be applied in the disease diagnosis and assessment of therapeutic interventions. 2 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →